Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04920708
Title Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression (FAIM)
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Royal Marsden NHS Foundation Trust
Indications

Her2-receptor negative breast cancer

Therapies

Fulvestrant + Ribociclib

Fulvestrant + Ipatasertib + Palbociclib

Fulvestrant + Palbociclib

Abemaciclib + Fulvestrant

Age Groups: adult | senior
Covered Countries


No variant requirements are available.